{"publication_id":"81e7fb2b-c79b-471e-af0e-954eb243b39b","traces":[{"claim_id":"claim_1","claim":"The cited direct receipts support a heterogeneous working map, not one uniform effect estimate across the bundle.","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_3","claim":"The surprise is the bounded heterogeneity: the cited direct receipts do not support one uniform effect estimate, so the useful alpha is the specific receipt map and its unresolved spread.","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_4","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_5","claim":"`fact_id=95208` (`A_core`) — relative risk reductions in cardiovascular mortality (38%) doi=10.2174/1573399812666160613113556","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_6","claim":"`fact_id=160907` (`A_core`) — SGLT2I use was associated with lower risks of cardiovascular (HR:0.64, 95% CI: [0.49-0.85], P = 0.0017) mortality doi=10.3389/fcvm.2021.747620","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]},{"claim_id":"claim_7","claim":"`fact_id=75215` (`A_core`) — lower glycated hemoglobin (HbA1c) by 0.6-0.8% (6-8 mmol/mol) without increasing the risk of hypoglycemia Source: SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?","candidate_sources":[{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","url":null},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","url":null},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","url":null},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","url":null},{"study":"Sodium‐Glucose Cotransporter‐2 Inhibitors and Primary Prevention of Atherosclerotic Cardiovascular Disease: A Meta‐Analysis of Randomized Trials and Systematic Review","doi":"10.1161/jaha.123.030578","url":null}]}]}